Jess Roper Net Worth

The estimated Net Worth of Jess Roper is at least $12.3 Milione dollars as of 22 March 2017. Mr. Roper owns over 2,000 units of Biolase Inc stock worth over $423 and over the last 17 years he sold BIOL stock worth over $12,250,049. In addition, he makes $0 as Independent Director at Biolase Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Roper BIOL stock SEC Form 4 insiders trading

Jess has made over 43 trades of the Biolase Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently he sold 2,000 units of BIOL stock worth $151,940 on 22 March 2017.

The largest trade he's ever made was exercising 25,000 units of Biolase Inc stock on 26 February 2014 worth over $190,750. On average, Jess trades about 4,253 units every 21 days since 2007. As of 22 March 2017 he still owns at least 8,452 units of Biolase Inc stock.

You can see the complete history of Mr. Roper stock trades at the bottom of the page.

Jess Roper biography

Jess Roper serves as Independent Director of the Company. Mr. Roper most recently served as the Senior Vice President and Chief Financial Officer of DexCom, Inc., where he held executive leadership positions from 2005 until retiring in April 2017. DexCom, Inc. is a medical device company focused on the design, development and commercialization of continuous glucose monitoring systems. While at DexCom, Inc., Mr. Roper also served as its Vice President and Chief Financial Officer and as the Director of Finance. During his tenure, DexCom, Inc. transitioned from a pre-revenue privately held medical device company to a multi-national, publicly traded entity. Mr. Roper previously held financial management positions with two other publicly traded companies and one venture-funded company. Earlier in his career, Mr. Roper was an auditor with PricewaterhouseCoopers and a bank and information systems examiner with the Office of the Comptroller of the Currency. Mr. Roper has a Master of Science degree in Corporate Accountancy and a Bachelor of Science degree in Business Administration in Finance from San Diego State University. He is a Certified Public Accountant and member of the Corporate Directors Forum. Mr. Roper brings to our Board business and operational experience, including capital markets experience.

How old is Jess Roper?

Jess Roper is 55, he's been the Independent Director of Biolase Inc since 2018. There are 9 older and 4 younger executives at Biolase Inc. The oldest executive at Biolase Inc is Richard R. Whipp, 69, who is the VP of Operations.

What's Jess Roper's mailing address?

Jess's mailing address filed with the SEC is 27042 TOWNE CENTRE DR., SUITE 270, FOOTHILL RANCH, CA, 92610.

Insiders trading at Biolase Inc

Over the last 12 years, insiders at Biolase Inc have traded over $9,258,543 worth of Biolase Inc stock and bought 25,366,011 units worth $28,515,794 . The most active insiders traders include Jack W Schuler, Larry Noracle Partners Lp O... e Larry N Feinberg. On average, Biolase Inc executives and independent directors trade stock every 57 days with the average trade being worth of $31,910. The most recent stock trade was executed by Jonathan T Md Lord on 7 December 2022, trading 3,537 units of BIOL stock currently worth $2,653.

What does Biolase Inc do?

biolase, inc. is a medical device company that develops, manufactures, markets, and sells laser systems in dentistry and medicine and also markets, sells, and distributes dental imaging equipment. biolase’s products are focused on better enabling clinicians to repair and restore patient’s dental conditions while reducing the pain, fear, and anxiety generally associated with dentistry. biolase is committed to elevating the standard of care in dentistry, while enabling clinicians to achieve better business returns.

Complete history of Mr. Roper stock trades at Biolase Inc e Dexcom Inc

Biolase Inc executives and stock owners

Biolase Inc executives and other stock owners filed with the SEC include:

• Todd Norbe,
  President, Chief Executive Officer, Director
• John Beaver,
  Chief Financial Officer, Executive Vice President
• John R. Beaver,
  Pres, CEO & Director
• Jonathan Lord,
  Independent Chairman of the Board
• Michael Polyviou,
  IR Contact Officer
• Elaine Wagner,
  Independent Director
• Garrett Sato,
  Independent Director
• Jess Roper,
  Independent Director
• Richard Lanman,
  Independent Director
• Michael DiTolla,
  Independent Director
• Richard Whipp,
  Vice President - Operations
• Richard R. Whipp,
  VP of Operations
• Jennifer Bright,
  VP of Fin.
• David Rodriguez,
  Director of Education & Events
• Brendan O'Connell,
  VP of Fin. and Corp. Controller
• Michael C. Carroll,
  Corp. Sec.
• Holger Arens,
  VP & MD of Europe, the Middle East & Africa
• Dr. Samuel B. Low,
  Chief Dental Officer and VP of Dental & Clinical Affairs
• Matthew Wilson,
  VP of HR
• Daniel Merkin,
  National Sales Director
• Larry Noracle Partners Lp O...,
  
• David C Dreyer,
  SVP / Chief Financial Officer
• Jack W Jack W. Schuler Livi...,
  
• Mark Joseph Nelson,
  SVP & Chief Financial Officer
• Paul N Clark,
  Director
• James R Talevich,
  Director
• Frederic H Moll,
  Director
• Harold C Jr. Flynn,
  President and CEO
• Jack W Schuler,
  
• Larry Noracle Partners Lp O...,
  
• Carol Gomez Dds Summerhays,
  Director
• Martha J. Dds, Ph D Somerman,
  Director
• Larry Noracle Partners Lp F...,
  
• Larry N Feinberg,
  10% owner
• Frederick D. Furry,
  Chief Financial Officer
• Jeffrey M Nugent,
  Acting Chief Executive Officer
• Samuel Bernard Low,
  Director
• Erin S. Enright,
  Director
• Alexander K. Arrow,
  President and COO
• Norman J. Nemoy,
  Director
• Gregory Lichtwardt,
  Director
• Federico Pignatelli,
  Chairman and CEO
• Kenneth P. Yale,
  Director
• Kathleen T O Loughlin,
  Director
• Steven Sandor,
  Chief Operating Officer
• Jennifer Bright,
  Chief Financial Officer
• Education Foundation Schuler,